Vaccine-Boosted CCP Decreases Virus Replication and Hastens Resolution of Infection Despite Transiently Enhancing Disease in SARS-CoV-2–Infected Hamsters
TD Carroll, T Wong, MK Morris… - The Journal of …, 2024 - academic.oup.com
Definitive data demonstrating the utility of coronavirus disease 2019 (COVID-19)
convalescent plasma (CCP) for treating immunocompromised patients remains elusive. To …
convalescent plasma (CCP) for treating immunocompromised patients remains elusive. To …
Tixagevimab+ cilgavimab against SARS-CoV-2: the preclinical and clinical development and real-world evidence
I Convertino, S Ferraro, E Cappello… - Expert Opinion on …, 2023 - Taylor & Francis
ABSTRACT Introduction Direct-acting SARS-CoV-2 antiviral monoclonal antibodies have
been an integral part of therapeutic strategies against COVID-19 pandemic. The monoclonal …
been an integral part of therapeutic strategies against COVID-19 pandemic. The monoclonal …
Predictors of high SARS-CoV-2 immunoglobulin G titers in COVID-19 convalescent whole-blood donors: a cross-sectional study in China
J Tang, H Liu, Q Wang, X Gu, J Wang, W Li… - Frontiers in …, 2023 - frontiersin.org
Background Demographic information has been shown to help predict high antibody titers of
COVID-19 convalescent plasma (CCP) in CCP donors. However, there is no research on the …
COVID-19 convalescent plasma (CCP) in CCP donors. However, there is no research on the …
Lessons learnt from the preclinical discovery and development of ensitrelvir as a COVID-19 therapeutic option
S Ferraro, I Convertino, E Cappello… - Expert Opinion on …, 2024 - Taylor & Francis
Introduction The COVID-19 pandemic stimulated the development of several therapeutic
tools with several degrees of success. Ensitrelvir, a protease inhibitor that blocks the …
tools with several degrees of success. Ensitrelvir, a protease inhibitor that blocks the …
Allosteric signal within the receptor-binding domain of the SARS-CoV-2 spike protein mediated by a class 3 monoclonal antibody revealed through molecular …
P Boonserm, W Somsoros, P Khunrae, K Charupanit… - ACS …, 2024 - ACS Publications
This study investigated the allosteric action within the receptor-binding domain (RBD) of the
SARS-CoV-2 spike protein caused by class 3 monoclonal antibody (mAb) binding. As the …
SARS-CoV-2 spike protein caused by class 3 monoclonal antibody (mAb) binding. As the …
[HTML][HTML] Administration of vaccine-boosted COVID-19 convalescent plasma to SARS-CoV-2 infected hamsters decreases virus replication in lungs and hastens …
TD Carroll, T Wong, MK Morris, C Di Germanio, Z Ma… - bioRxiv, 2023 - ncbi.nlm.nih.gov
The utility of COVID-19 convalescent plasma (CCP) for treatment of immunocompromised
patients who are not able to mount a protective antibody response against SARS-CoV-2 and …
patients who are not able to mount a protective antibody response against SARS-CoV-2 and …
[HTML][HTML] Next-generation treatments: Immunotherapy and advanced therapies for COVID-19
JA Arevalo-Romero, SM Chingaté-López, BA Camacho… - Heliyon, 2024 - cell.com
The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), emerged in 2019 following prior outbreaks of coronaviruses like SARS and …
(SARS-CoV-2), emerged in 2019 following prior outbreaks of coronaviruses like SARS and …
Exploring the use of monoclonal antibodies and antiviral therapies for early treatment of COVID-19 outpatients in a real-world setting: a nationwide study from England …
F Ciccimarra, N Luxi, C Bellitto, L L'Abbate, P De Nardo… - BioDrugs, 2023 - Springer
Background Real-world data on early treatment of coronavirus disease 2019 (COVID-19)
outpatients with newly approved therapies are sparse. Aim To explore the pattern of use of …
outpatients with newly approved therapies are sparse. Aim To explore the pattern of use of …
Effects of the COVID-19 pandemic: new approaches for accelerated delivery of gene to first-in-human CMC data for recombinant proteins
H Broly, J Souquet, A Beck - MAbs, 2023 - Taylor & Francis
The COVID-19 pandemic highlighted the urgent need for life-saving treatments, including
vaccines, drugs, and therapeutic antibodies, delivered at unprecedented speed. During this …
vaccines, drugs, and therapeutic antibodies, delivered at unprecedented speed. During this …
Cryptic-site-specific antibodies to the SARS-CoV-2 receptor binding domain can retain functional binding affinity to spike variants
The COVID-19 pandemic, caused by the SARS-CoV-2 virus, has accumulated more than
700 million infection cases and 6.9 million deaths. New variants have affected antibody …
700 million infection cases and 6.9 million deaths. New variants have affected antibody …